The US Food and Drug Administration (FDA) has approved St Jude Medical's Unify Quadra cardiac resynchronization therapy defibrillator (CRT-D) and Quartet Left Ventricular Quadripolar Pacing Lead for managing heart failure patients.

The Quartet lead features four electrodes which are spaced over 4.7 centimeters and can be used up to 10 pacing configurations which facilitates physicians to implant the lead closer to the base of the left ventricle.

The Quartet pacing lead utilizes the QuickFlex µ lead platform which is featured with Optim insulation, that unites the biostability and flexibility of silicone rubber to offer more durability.

The company claims that the system is also FDA cleared to be used with Patient Care Network for remotely managing the patient.

Central Baptist Hospital Lexington Cardiology Gery Tomassoni said in addition to not needing to compromise between lead stability and electrical performance when placing the lead, the Quartet lead shows excellent handling characteristics that make the implant procedure more efficient.